Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will ...

As global markets navigate a busy earnings season with mixed signals from economic data, major indices like the Nasdaq Composite and S&P MidCap 400 have experienced volatility, highlighting investor ...

TB Alliance is honored to join today's High-Level Meeting hosted by the Indonesian Ministry of Health. Leaders and experts in tuberculosis (TB) have convened to discuss strategies, innovations, and ...

KT&G Corporation ("KT&G" or the "Company") (KRX:033780), announced the 'KT&G Corporate Value-up Plan' on the 7th, that includes their goal of achieving 15% ROE and returning KRW 3.7 trillion to ...

In such an environment, identifying high growth tech stocks like ALTEOGEN can be crucial for investors seeking to capitalize on robust earnings potential and long-term growth prospects.

South Korea’s Alteogen (Kosdaq: 196170) has signed an exclusive licensing agreement with Japanese pharmaceutical company ...

Alteogen, Biocity Biopharmaceutics, and others are evaluating novel antibody-drug conjugates candidates to improve the treatment landscape. Key antibody-drug conjugates in oncology pipeline in various ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Discover how AI is ...